Announcing our next Therapeutics Letter: Twenty-Five Pearls from 25 years
Announcing our next Therapeutics Letter: Twenty-Five Pearls from 25 years … [Read more...]
[122] Twenty-Five Pearls from 25 years (part 2)
In this Letter, the second in a 2-part anniversary series, we present the remaining 12 “clinical pearls” found in Therapeutics Letters published between 2006 and 2018. The Therapeutics Initiative is celebrating its 25th anniversary this year, in part by highlighting some key conclusions from the 120 issues of the Therapeutics Letter published so far. 14: The majority of new drugs do NOT represent … [Read more...]
[121] Twenty-Five Pearls from 25 years (part 1)
The Therapeutics Initiative is celebrating its 25th anniversary this year, in part by highlighting key conclusions from the 120 issues of the Therapeutics Letter published so far. In this first of a 2-part series we present 13 “clinical pearls” found in Letters published between 1994 and 2005. 1: Thiazides are clearly the drug of first choice for the treatment of uncomplicated hypertension Drugs … [Read more...]
[120] Routine VTE prophylaxis: Is there a net health benefit?
Prophylaxis of venous thromboembolism (VTE) with low molecular weight heparin (LMWH) is now common for hospitalized non-surgical patients in British Columbia and much of North America. This includes patients who are at very low risk for a VTE. VTE events include deep vein thrombosis (DVT), usually in the legs, which can be either symptomatic or asymptomatic, as well as pulmonary embolism … [Read more...]
[119] Epinephrine autoinjectors available in Canada
Anaphylaxis is one of the most dramatic health crises. Experiencing or witnessing this acute and serious allergy event is a powerful incentive to learn more, yet many health care professionals must act without the benefit of personal experience. The Canadian Institute for Health Information estimates that anaphylaxis makes up 8% of the approximately 171,000 annual emergency department visits for … [Read more...]
Policy-induced selection bias in pharmacoepidemiology: The example of coverage for Alzheimer’s medications in British Columbia
Fisher A, Carney G, Bassett K, Maclure KM, Dormuth CR … [Read more...]
Influence of opioid prescribing standards on drug use among patients with long-term opioid use: a longitudinal cohort study
Morrow RL, Bassett K, Wright JM, Carney G, Dormuth CR … [Read more...]
Outcomes associated with hospital admissions for accidental opioid overdose in British Columbia: a retrospective cohort study
Morrow RL, Bassett K, Maclure M, Dormuth CR … [Read more...]
Tramadol and the risk of seizure: nested case-control study of US patients with employer-sponsored health benefits
Morrow RL, Dormuth CR, Paterson M, Mamdani MM, Gomes T, Juurlink DN; Canadian Drug Safety Effectiveness Research Network (CDSERN) … [Read more...]
[118] Trends in utilization of proton pump inhibitors in British Columbia
The first three Therapeutics Letters focused on complaints related to the upper gastrointestinal tract, a common presentation to the primary care physician.1-3 These Letters reviewed evidence about H2-blockers, eradication of Helicobacter pylori, and drugs used for gastroesophageal reflux. However, they also raised concerns about chronic acid suppression by daily dosing of omeprazole, the first … [Read more...]
- 1
- 2
- 3
- …
- 24
- Next Page »
